Additionally, it is important to note that neither trial combined PARP and endocrine therapy; therefore, olaparib and talazoparib are approved as monotherapies even for HR[+] advanced breast cancer, and it is unknown if the addition of endocrine therapy to PARP inhibitors could have a synergistic effect in these patients. The gene discussed is PARP1; the disease is breast carcinoma.